U.S. markets closed

Charles River Laboratories International, Inc. (CRL)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
265.48-8.06 (-2.95%)
At close: 4:00PM EST

265.48 -0.05 (-0.02%)
After hours: 4:04PM EST

Charles River Laboratories International, Inc.

251 Ballardvale Street
Wilmington, MA 01887
United States
781 222 6000

IndustryDiagnostics & Research
Full Time Employees17,100

Key Executives

NameTitlePayExercisedYear Born
Mr. James C. FosterChairman, CEO & Pres5.38M5.16M1951
Mr. David Ross SmithCorp. Exec. VP & CFO1.25M871.77k1966
Mr. Joseph W. LaPlumeCorp. Exec. VP of Corp. Devel. & Strategy931.56k574.73k1974
Ms. Birgit GirshickCorp. EVP of Global Discovery & Safety Assessment, Biologics Testing Solutions & Avian Vaccine937.58k440.65k1970
Mr. Michael Gunnar KnellCorp. Sr. VP & Chief Accounting OfficerN/AN/A1977
Mr. Arthur C. HubbsCorp. Sr. VP & Chief Information OfficerN/AN/AN/A
Todd SpencerCorp. VP of Investor RelationsN/AN/AN/A
Mr. Matthew L. DanielCorp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance OfficerN/AN/AN/A
Ms. Amy CianciarusoCorp. VP of PR & Corp. CommunicationsN/AN/AN/A
Ms. Gina M. MullaneChief Marketing Officer & Corp. Sr. VPN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company has a strategic partnership with PathoQuest SAS to establish a next generation sequencing based testing laboratory. Charles River Laboratories International, Inc. is based in Wilmington, Massachusetts.

Corporate Governance

Charles River Laboratories International, Inc.’s ISS Governance QualityScore as of January 22, 2021 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 4; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.